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Bioanalysis is determining the concentration of drugs and
metabolites in biological fluids (i.e. plasma and urine). During
the past 15years tremendous advances in bioanalysis, for example
HPLC, auto injectors, data collection systems and robotics has
enabled the productivity of,the bioanalyst to increase but it still
requires considerable manual intervention. This paper describes the
rationale, the justification and the plans Bristol-Myers
Squibb has to completely automate the entire bioanalytical process.
Fifteen years ago bioanalysis was extremely tedious.
Q.uantitating drugs in plasma and urine was accomplished
by either RIA or GC. Although RIA was non-specific, and
raising appropriate antibodies bordered on black magic,
this was often preferred over the labour-intensive GC.
GC required tedious chemical derivatization with
manual injection, followed by manual chromatographic
integration. When HPLC was introduced in the 1970s, it
proved to be a fantastic technological advance in
bioanalysis because it offered specificity without the need
tbr chemical derivatization. Unfortunately, HPLC still
required manual injection and manual chromatographic
integratio.n. When autoinjectors and chromatographic
integrators became available they quickly increased the
productivity ofboth GC and HPLC. These advances only
addressed the obvious needs of the chromatographic
portion ofsample bioanalysis. However, sample extraction
and preparation was still performed manually. The
introduction of fast LC systems with air bubbles as
separators was an attempt to automate the sample
extraction portion of bioanalyis. Unfortunately, this
technology did not prove to be robust. Zymark’s robotic
stations were successthl at automating the sample
extraction steps.
Many people consider their bioanalytical laboratories
automated if they have Zymark robots, automatic
injectors and data reduction systems. As shown in figure
1, there are many steps involved in bioanalysis and the
commercially available equipment will only address the
sample analysis step. Clearly, considerably more can be
automated in this bioanalytical process. In fact, the entire
system should be able to be automated if it were
economically beneficial.
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Figure 1. Sample handling steps.
laboratories. Without the use of robotics the typical
in-house analyst can prepare a bioanalytical run every
other day. The average bioanalytical run contains about
90 injections, 20 of which are standards and quality
control samples. Therefore, the typical analyst can process
about 175 unknown samples per week. During 1992 about
63000 samples were sent to contract bioanalytical
laboratories for bioanalysis for two reasons.-First,
Bristol-Myers Squibb has inadequate facilities for
handling samples known to be HIV+. Therefore, any
known HIV + sample is sent out for bioanalysis. Second,
with the current level of automation within the
bioanalytical department it was impossible to handle the
tremendous quantity ofsamples. It should be stressed that
sending samples to contract laboratories for bioanalysis
only saves about two thirds of the resources that would
be used for in-house bioanalysis. The analyst in
Bristol-Myers Squibb is still responsible for verifying the
bioanalytical results and for getting the data in a format
for subsequent pharmacokinetic analysis. It costs on
average about $38 per sample for outside contract
bioanalysis. However, the real.cost of sending samples to
contract laboratories for bioanalysis is $60 per sample,
taking into account both the contract and in-house costs.
During 1992, Bristol-Myers Squibb spent $2.4 M dollars
on bioanalytical contracts.
Total automation
During 1992 Bristol-Myers Squibb generated about
200 000 bioanalytical samples that needed to be analysed.
Of these samples about two-thirds of them were analysed
in-house and the remainder were sent to contract
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If the entire bioanalytical process were to be automated
at Bristol-Myers Squibb, the goals would be:
(1) Increase productivity--go from 175 to 1500 samples/
week/analyst.
(2) Increase capacity--plan to process 400 000 samples/
year.
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Figure 3. Sample login and decontamination station.
(3) Reduce reliance on contract laboratories and save
millions of dollars each year.
(4) Improve analyst safety from blood-born diseases and
be able to bring HIV+ samples in-house for
bioanalysis.
(5) Maximize the time that expensive equipment is
utilized by continuously feeding it samples.
(6) Accelerate drug development by processing samples
at a faster rate.
(7) Improve our sample tracking capabilities that are
often done manually.
(8) Improve worker morale.
A 40 ft x 100 ft automation bioanalytical laboratory that
addresses all of the sample processing steps described in
figure is shown in figure 2. Sample flow in this laboratory
moves from right to left. Sample receipt and its subsequent
decontamination occur in the room on the right.
A schematic for the automated sample login and
decontamination station is shown in figure 3. Following
decontamination the samples are sent into a large freezer
for storage at -20C. This freezer has been named the
’AS/RS’--the automatic storage and retrieval system.
The freezer has two linear tracks on which robots move
to place on and pick off 50 tube trays from storage racks.
This process can be viewed very much like an automated
warehouse, only it is smaller and colder. During sample
bioanalysis, selected samples are removed from their trays
in the freezer and placed into 20 tube trays for transport
to the bioanalysis stations. The trays are transported to
the bioanalysis stations by simple conveyor belts. The
trays are removed from the conveyor belts by a robot and
placed on the bioanalysis station. After an aliquot has
been taken from each sample in the tray, the tray is then
placed back on the conveyor belt for transport back to
the AS/RS for storage. A schematic ofthe transport system
shown in figure 4. The final step in the automation
process (sample bioanalysis) has already been fully
automated. The sample bioanalysis process consists of
extraction, chromatographic separation, measurement
and quantitation.
Managing this automation laboratory will require
considerably different skills than are currently envisioned
in a research environment. For example, the goal of this
laboratory is to run 24 hours a day, seven days a week.
Managing that work will require production management
as well as scientific management training. It is anticipated
that the entire automation laboratory with 12 bioanalysis
stations will require a staff of six bioanalytical scientists,
two computer scientists, one decontamination technician
and one manager. That is two bioanalysis stations per
scientist. Handling the current sample workload would
be simple in this laboratory. For example, if 11 of the 12
bioanalysis stations process one sample every 15 minutes,
24 hours a day, five days per week and 40 weeks per year,
the result would be well over 200000 samples being
analysed. Sample capacity could easily be increased by
either increasing sample throughput per bioanalysis
station, and/or by working more days/week, and/or by
adding more bioanalysis stations. Clearly, increasing
sample throughput would be the preferred choice.
The entire cost estimate of this automation laboratory
ranges from $4 500 000 to $7 000 000. The hardware alone
will cost about $2500000 with software/engineering
costing between $2 000 000 to $4 500 000. The large range
in software expense is dependent upon what internal
resources can be devoted to this project. The question
that is often asked is whether this automation laboratory
will be economically justifiable? Figures 5 and 6 address
this question. Figure 5 compares the per sample
bioanalytical cost between automated sample bioanalysis
versus manual sample bioanalysis. As the number of
samples increases, the cost of performing automated
bioanalysis decreases to about $38 per sample. The figure
of$38 per sample amount represents the high side of total
sample bioanalysis because the scientist performing the
bioanalysis was still responsible for manually logging in
the samples, for tracking the samples, for transporting the
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Figure 6. Bioanalytical cost comparison.
samples to the laboratory and for s.etting up the analytical
run. In figure 6 the total sample bioanalysis cost in
millions of dollars, versus the annual number of samples
analysed in-house, is plotted comparing the in-hour/
contract cost of $60 per sample against the automation
sample bioanalysis cost of $38 per sample. These cost
comparisons were used to perform a return on investment
analysis. Under the worst case scenario that the total cost
of the automation laboratory was 35 more than
$7000000, that the efficiency of the automation lab
was 35 less than projected (efficiency was one
sample processed every 15 minutes per sample bioanalysis
station) and that the sample capacity stayed the same,
this system would pay for itself in less than three years.
Creating this bioanalytical automation laboratory
produced several new and excisting challenges. First, this
laboratory will force the company to redefine a
bioanatytical experiment. For example, today’s bio-
analytical experiment consists of 11-12 standards, 6-8
quality control (QC) samples and 60-100 unknown study
samples. In the continuous feed automation laboratory
the potential exists for a bioanalytical experiment to
contain 500-1000 samples. In an experiment of this size
how many standards and QCs are appropriate? Also, how
should the standards and QCs be placed in the
run? Second, chromatographic software will need to
be developed that can diagnose problems with the
experiment and can then terminate that experiment.
Third, LCMS machines will be interfaced with this
system. This equipment has the ability to accept a new
sample every four minutes. With the continuous-feed
automation laboratory, the rate limiting step is the sample
extraction process. Manufacturers will need to develop
technology that greatly increases the speed of that
bioanalytical step.
Conclusion
In conclusion, a vision for automating bioanalysis has
been presented. This vision moves away from the historical
perspective that the only steps in bioanalysis that need to
be automated are the sample extraction step, the sample
separation and measurement step and the sample
quantitation step. This vision offers the potential for
increased productivity, increased capacity and increased
"worker safety. This vision was turned into a plan; albeit
an expensive plan but with the potential for big monetary
savings. This plan in a relatively low-risk plan, because
similar systems have been successtially implemented such
as warehousing and clinical chemistry operations.
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